Wegovy (Semaglutide)
$240.00Wegovy (semaglutide 2.4 mg) is an FDA-approved injectable prescription medication specifically indicated for chronic weight management in adults with obesity or overweight conditions.
Why Choose Wegovy?
Formulated with higher therapeutic target dosages specifically optimized for long-term weight reduction and maintenance.
How to Use
Use once weekly on the same day. Start with 0.25 mg weekly for Month 1, gradually titrating every 4 weeks up to the maintenance dose of 2.4 mg.
Safety Information
Contraindicated in patients with medullary thyroid carcinoma history. Stay well hydrated throughout treatment to avoid dehydration.
Potential Side Effects
Gastrointestinal symptoms like nausea, heartburn, burping, fatigue, and headache may occur, particularly during dose increases.
Product Facts
| Generic Name | Semaglutide |
| Brand Name | Wegovy |
| Type of Medication | GLP-1 Receptor Agonist for Weight Management |
| FDA Approval Date | June 4, 2021 |
| Indications | Indicated for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition. |
| Dosage Forms | Single-dose prefilled pens (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) |
| Administration | Once weekly subcutaneous injection |
| Special Precautions | Risk of thyroid C-cell tumors. Advise patients of symptoms of acute pancreatitis and gallbladder disease. |
| Drug Interactions | May impact the absorption of concurrently administered oral medications due to delayed gastric emptying. |
| Use in Specific Populations | Do not use during pregnancy. Nursing mothers should consult with their healthcare practitioner. |
| Prescription | Prescription Required |
| Manufacturer | Novo Nordisk |
How to Buy
Select your titration level, order securely online, and benefit from expert medical support and temperature-controlled shipping.